Larimar Therapeutics, Inc.
LRMR
$4.36
$0.092.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 44.81% | 30.62% | 4.08% | 5.02% | -9.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.60% | -0.23% | 104.58% | 171.02% | 12.98% |
| Operating Income | -23.60% | 0.23% | -104.58% | -171.02% | -12.98% |
| Income Before Tax | -25.21% | -1.13% | -116.83% | -207.84% | -21.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.21% | -1.13% | -116.83% | -207.84% | -21.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.21% | -1.13% | -116.83% | -207.84% | -21.06% |
| EBIT | -23.60% | 0.23% | -104.58% | -171.02% | -12.98% |
| EBITDA | -23.76% | 0.15% | -104.80% | -171.64% | -13.03% |
| EPS Basic | 23.18% | 28.33% | -62.43% | -150.80% | -20.62% |
| Normalized Basic EPS | 23.20% | 28.31% | -62.45% | -150.79% | -20.62% |
| EPS Diluted | 23.18% | 28.33% | -62.43% | -150.80% | -20.62% |
| Normalized Diluted EPS | 23.20% | 28.31% | -62.45% | -150.79% | -20.62% |
| Average Basic Shares Outstanding | 63.03% | 41.11% | 33.49% | 22.75% | 0.35% |
| Average Diluted Shares Outstanding | 63.03% | 41.11% | 33.49% | 22.75% | 0.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |